国浩律师（杭州）事务所 关 于 山东赛托生物科技股份有限公司 2023 年第二次临时股东大会法律意见书 致：山东赛托生物科技股份有限公司 一、关于本次股东大会的召集、召开程序 （一）公司董事会已于 2023 年 7 月 31 日在巨潮资讯网（http://www.cnin fo.com.cn）上刊载了《山东赛托生物科技股份有限公司关于召开 2023 年第二次 临时股东大会通知的公告》（以下简称"会议通知"）。会议通知中载明了本次 股东大会的会议召开时间、会议召开地点、会议召集人、会议召开及表决方式、 会议审议事项、会议出席对象、会议登记方法、会议联系方式等事项，说明了股 东有权亲自或委托代理人出席本次股东大会并行使表决权。由于本次股东大会采 取现场投票和网络投票相结合的方式，公司在会议通知中还对网络投票的投票时 间、投票程序等有关事项做出了明确说明。 国浩律师（杭州）事务所（以下简称"本所"）接受山东赛托生物科技股份 有限公司（以下简称"公司"）委托，指派律师出席公司 2023 年第二次临时股 东大会（以下简称"本次股东大会"），并依据《中华人民共和国公司法》（以 下简称"《公司法》"）、《中华人民共和国证券 ...

1、本次股东大会不存在否决议案的情形； 2、本次股东大会不涉及变更前次股东大会决议的情形。 一、会议召开和出席情况 证券代码：300583 证券简称：赛托生物 公告编号：2023-054 山东赛托生物科技股份有限公司 2023 年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 特别提示： （一）会议召开情况 山东赛托生物科技股份有限公司（以下简称"公司"）2023 年第二次临时股 东大会会议通知于 2023 年 7 月 31 日以公告形式发出，本次股东大会采取现场投 票和网络投票相结合的方式召开。其中，现场会议于 2023 年 8 月 16 日（星期三） 14:30 在公司会议室召开。通过深圳证券交易所交易系统进行网络投票的时间为： 2023 年 8 月 16 日 9:15-9:25，9:30-11:30，13:00-15:00。通过深圳证券交易所 互联网系统投票的具体时间为 2023 年 8 月 16 日 9:15-15:00。 本次会议由公司董事会召集，米奇先生主持，公司的董事、监事、高级管理 人员和见证律师等出席或列席会议。本 ...

证券代码：300583 证券简称：赛托生物 公告编号:2023-053 山东赛托生物科技股份有限公司 关于召开 2023 年第二次临时股东大会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 山东赛托生物科技股份有限公司（以下简称"公司"）第三届董事会第十九 次会议决定于 2023 年 8 月 16 日（星期三）召开 2023 年第二次临时股东大会（以 下简称 "本次股东大会"），会议通知已于 2023 年 7 月 31 日刊登于中国证监会 指定的创业板信息披露网站。现将股东大会的有关事宜提示如下： 一、召开会议的基本情况 1、股东大会届次：2023 年第二次临时股东大会 2、会议召集人：公司董事会 3、会议召开的合法、合规性：本次股东大会会议的召开符合有关法律、行 政法规、部门规章、规范性文件和《公司章程》等规定。 4、会议召开日期和时间 现场会议召开时间：2023 年 8 月 16 日（星期三）下午 14:30 网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为：2023 年 8 月 16 日 9:15-9:25，9:30-11:30 ...

Financial Performance - The company's operating revenue for the first half of 2023 reached ¥663,655,673.27, an increase of 4.31% compared to ¥636,242,960.65 in the same period last year[21]. - Net profit attributable to shareholders was ¥59,967,581.48, representing an 85.43% increase from ¥32,339,106.58 in the previous year[21]. - Basic and diluted earnings per share increased to ¥0.55, up 83.33% from ¥0.30 in the previous year[21]. - The company reported a significant increase in net profit after deducting non-recurring gains and losses, which reached ¥37,125,683.51, a 20.73% increase from ¥30,750,102.42 in the previous year[21]. - The company achieved a net profit of CNY 59,967,581.48 for the first half of 2023, with a parent company net profit of CNY 40,670,451.84[116]. - The company reported a total comprehensive income of CNY 63,455,115.72 for the first half of 2023, compared to CNY 30,385,506.16 in the previous year[199]. - The company's revenue for the reporting period reached ¥663,655,673.27, representing a year-on-year increase of 4.31% compared to ¥636,242,960.65 in the same period last year[58]. - The gross profit margin for steroid drug raw materials was 29.15%, showing an increase of 4.95% year-on-year[61]. Cash Flow and Assets - The net cash flow from operating activities was negative at -¥117,369,579.22, a decline of 164.23% compared to ¥182,721,185.87 in the same period last year[21]. - Cash and cash equivalents increased by 190.15% to ¥196,875,958.76, up from ¥67,853,561.20, primarily due to the influx of funds from the capital increase[58]. - The company's total assets as of June 30, 2023, were ¥3,506,106,963.83, reflecting a growth of 17.04% from ¥2,995,140,143.52 at the end of the previous year[22]. - The company's current assets reached CNY 1,625,846,289.28 as of June 30, 2023, compared to CNY 1,139,941,599.15 at the beginning of the year, indicating a rise of about 42.6%[191]. - The total liabilities increased to CNY 1,421,629,861.62 from CNY 1,224,800,344.70, reflecting a growth of approximately 16.1%[193]. - The company's equity attributable to shareholders rose to CNY 2,027,241,953.83 as of June 30, 2023, up from CNY 1,720,136,902.94, marking an increase of around 17.8%[193]. Investments and Projects - The company plans to distribute 6 new shares for every 10 shares held, utilizing capital reserves[6]. - Research and development investment increased by 41.91% to ¥27,913,511.71, up from ¥19,670,389.92, aimed at accelerating project progress[58]. - The total investment during the reporting period was CNY 59,966,853.47, representing a 20.09% increase compared to CNY 49,933,124.73 in the same period last year[70]. - The company has committed to producing 180 tons of dihydroxy yellow ketone, with ongoing developments in this area[84]. - The company plans to invest 270 million yuan into a new project for steroid intermediates and raw materials, with a total investment of 450.91 million yuan[90]. Market Position and Strategy - The company operates in the pharmaceutical manufacturing industry, focusing on steroid drugs, and is positioned in the upper-middle stream of the pharmaceutical supply chain[32]. - The company is actively pursuing international market expansion, evidenced by the issuance of a European pharmacopoeia suitability certificate for one of its raw materials[38]. - The company has established long-term strategic partnerships with major pharmaceutical companies, enhancing its market position and brand recognition[53]. - The company is focused on upgrading its entire industry chain, linking intermediates, raw materials, and formulations to improve cost and quality control[55]. - The company is committed to enhancing its research and development capabilities to maintain a leading position in the industry[106]. Environmental Compliance - The company emphasizes environmental protection and has implemented measures to comply with strict safety and environmental regulations[107]. - The company has implemented a wastewater treatment system that combines advanced physical and chemical processes, including multi-effect evaporation and Fenton oxidation, to ensure compliance with environmental standards[124]. - The company has classified and treated exhaust gases from various processes using methods such as alkaline spraying and catalytic oxidation, ensuring stable emissions that meet regulatory standards[125]. - The company has established a comprehensive waste management system, including separate storage for hazardous waste and measures to prevent leakage[126]. - The company has committed to zero emissions of various industrial solid wastes, ensuring no discharge into the external environment[128]. Shareholder Information - The company plans to increase its total share capital by 71,138,297 shares through a capital reserve transfer, resulting in a total share capital of 189,702,126 shares[116]. - The total number of shares outstanding is now 118,563,829, with 104,387,067 shares being unrestricted[169]. - The largest shareholder, Shandong Runxin Investment Co., Ltd., holds 22.82% of the shares, totaling 27,060,864 shares[179]. - The company has a six-month lock-up period for the newly issued shares[176]. - The company’s major shareholders have pledged a significant portion of their shares, with the first major shareholder pledging 80% of their holdings[181].

证券代码：300583 证券简称：赛托生物 山东赛托生物科技股份有限公司 投资者关系活动记录表 编号：DY2023-001 □特定对象调研 □分析师会议 □媒体采访 业绩说明会 投 资 者关 系 活 动类别 □新闻发布会 □路演活动 □现场参观 □其他 参 与 单位 名 称 及人员姓名 参与公司 2022 年度业绩网上说明会活动的投资者 时间 2023 年 5 月 5 日 15:00-17:00 地点 "全景•路演天下"平台（http://ir.p5w.net） "价值在线"平台（www.ir-online.cn） 董事长米奇先生 总经理靳连标先生 上 市 公司 接 待 人员姓名 董事、副总经理、董事会秘书李璐女士 财务总监李福文先生 独立董事卿北军先生 公司于 2023 年 5 月 5 日 15:00-17:00 在"全景•路演天下" （http://rs.p5w.net）和"价值在线"（www.ir-online.cn）举办 2022 年度业绩网上说明会，本次业绩说明会采用网络远程的方式举 行，问答环节主要内容如下： 投 资 者关 系 活 动 主 要内 容 介 绍 1、问：董事长你好，去年出台了十四五规划 ...

Financial Performance - The company's revenue for Q1 2023 was CNY 334,785,915.82, representing a 31.99% increase compared to CNY 253,646,857.08 in the same period last year[4] - Net profit attributable to shareholders for Q1 2023 was CNY 15,355,110.28, up 20.53% from CNY 12,739,991.21 in Q1 2022[4] - The company's operating profit was ¥19,947,417.76, an increase of 42% from ¥14,066,025.89 in the same period last year[26] - Net profit for Q1 2023 was ¥17,525,308.93, representing a 49% increase compared to ¥11,721,511.57 in Q1 2022[26] - Total operating revenue for Q1 2023 reached ¥334,785,915.82, a 32% increase from ¥253,646,857.08 in Q1 2022[25] - Total operating costs amounted to ¥313,685,870.45, up 31% from ¥239,159,017.57 in the previous year[25] - The company reported a total comprehensive income of ¥15,999,364.10 for Q1 2023, compared to ¥7,060,494.22 in Q1 2022[26] Cash Flow and Liquidity - The net cash flow from operating activities increased by 16.45% to CNY 10,704,060.35, compared to CNY 9,191,765.31 in the previous year[4] - The cash inflow from operating activities for Q1 2023 was CNY 248,042,987.04, a decrease of 11.7% compared to CNY 281,019,424.09 in the previous period[28] - The total cash outflow from operating activities was CNY 237,338,926.69, down from CNY 271,827,658.78 in the previous period[28] - The cash received from sales of goods and services was CNY 239,332,850.86, a decrease from CNY 243,366,071.04 in the previous period[28] - The cash paid for purchasing goods and services was CNY 92,594,498.30, an increase from CNY 48,014,507.18 in the previous period[28] - The cash paid to employees was CNY 42,219,708.05, an increase from CNY 39,952,522.80 in the previous period[28] - The net cash outflow from investing activities was CNY -27,232,006.03, an improvement from CNY -59,898,407.34 in the previous period[29] - The cash inflow from financing activities totaled CNY 381,974,721.80, up 36.4% from CNY 280,000,000.00 in the previous period[29] - The net cash flow from financing activities was CNY 6,643,103.13, a significant decrease of 87.5% compared to CNY 53,181,054.01 in the previous period[29] - The ending balance of cash and cash equivalents was CNY 46,054,445.31, down from CNY 61,832,290.63 in the previous period[29] - The company's cash and cash equivalents increased to ¥249,546,369.14 from ¥188,398,286.35 at the beginning of the year, representing a growth of 32.4%[22] Assets and Liabilities - The total assets at the end of Q1 2023 were CNY 3,107,308,236.19, a 3.75% increase from CNY 2,995,140,143.52 at the end of the previous year[4] - Total liabilities increased to ¥1,320,411,681.70, compared to ¥1,224,242,953.13 in the previous year[24] - The company’s total liabilities increased, with accounts payable rising by 43.00% to CNY 20,851.59 million due to increased payments made via bank acceptance bills[9] - Accounts receivable rose to ¥244,889,134.78 from ¥196,565,259.17, an increase of 24.6%[22] - Inventory increased to ¥635,759,362.23 from ¥608,261,782.36, reflecting a growth of 4.5%[22] - Total equity reached ¥1,786,896,554.49, slightly up from ¥1,770,897,190.39 in Q1 2022[24] Research and Development - Research and development expenses surged by 96.16% to CNY 1,399.94 million, reflecting accelerated project advancements[12] - Research and development expenses rose to ¥13,999,442.81, a significant increase of 96% from ¥7,136,868.14 in Q1 2022[25] Shareholder Information - Total number of common shareholders at the end of the reporting period is 10,821[17] - The largest shareholder, Shandong Runxin Investment Co., Ltd., holds 25.31% of shares, totaling 27,060,864 shares[17] - The company has a total of 27,154,364 shares held by major shareholders participating in financing activities[18] Regulatory and Market Activities - The company received approval from the China Securities Regulatory Commission for a stock issuance on March 29, 2023[19] - The company plans to expand its market presence following the successful registration of new shares[19] Return on Equity - The weighted average return on equity increased to 0.89% from 0.75% in the previous year[4] - The company reported a basic earnings per share of CNY 0.14, which is a 16.67% increase from CNY 0.12 in the same quarter last year[4] - Basic and diluted earnings per share for Q1 2023 were both ¥0.14, up from ¥0.12 in Q1 2022[26]

山东赛托生物科技股份有限公司2022年年度报告全文 ...

山东赛托生物科技股份有限公司 关于举行2022年度业绩网上说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 山东赛托生物科技股份有限公司（以下简称"公司"）《2022 年年度报告》 及其摘要于 2023 年 4 月 25 日刊登在中国证监会指定的创业板信息披露网站巨潮 资讯网。为了让广大投资者进一步了解公司 2022 年年度经营情况，公司定于 2023 年 5 月 5 日（星期五）15:00-17:00 在"全景网"和"价值在线"双平台采用网 络互动的方式举办 2022 年年度业绩说明会，投资者可根据习惯和方便选择登陆 "全景•路演天下"（http://rs.p5w.net）和"价值在线"（www.ir-online.cn） 任一平台参与本次年度业绩说明会。 证券代码：300583 证券简称：赛托生物 编号：2023-030 （全景•路演天下问题征集页面二维码） （价值在线问题征集页面小程序） 敬请广大投资者提前提交您所关注的问题，便于公司在业绩说明会上对投资 者普遍关注的问题进行回答，提升此次业绩说明会的针对性。 欢迎广大投资者积极参与本次网上说 ...

编号：DY2021-002 证券代码：300583 证券简称：赛托生物 山东赛托生物科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------| | | □特定对象调研 □分析师会议 | | | | □媒体采访 □业绩说明会 | | | 投资者关系活 | □新闻发布会 □路演活动 | | | 动类别 | □现场参观 | | | | 其他 （山东辖区上市公司 | 2021 年度投资者网上集体接待日活动） | | 参与单位名称 及人员姓名 | 参与公司 2021 | 年度投资者网上集体接待日活动的投资者 | | 时间 | 2021 年 11 月 16 日 | 14:00-16:00 | | 地点 | 全景网"投资者关系互动平台"（ | http ...

编号：DY2022-001 证券代码：300583 证券简称：赛托生物 山东赛托生物科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |---------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------| | | 特定对象调研 □分析师会议 | | | | □媒体采访 □业绩说明会 | | | 投资者关系活 动类别 | □新闻发布会 □路演活动 | | | | □现场参观 | | | | 其他 （电话会议） | | | 参与单位名称 及人员姓名 | 招商信诺资产管理有限公司 | 翟琳琳、余懿、詹孝颖、吴璐芸 | | 时间 | 2022 年 1 月 7 日 | 16:00-17:30 | | 地点 | 电话会议 | | | 上市公司接待 人员姓名 | 董事、副总经理、董事会秘书：李璐女士 证券事务代表：曾庆利女士、郭一 ...